However, the risk of HBV reactivation in HBsAg−/HBcAb+ patients receiving anti-TNF therapy is uncertain [12–14, 18–22]; there have been reports of HBV reactivation with fulminant hepatitis that necessitated antiviral therapy in such patients and even fatal hepatic failure [13, 18, 23–25], whereas others have found anti-TNF to be generally safe in this setting, even without anti-HBV prophylaxis [14, 19–22, 26]. Here, TNF is linked to Fulminant hepatitis.